Press Room

50th Organic Process Research and Development Conference (OPRD)

Start
Monday, October 02, 2023 - 09:00
End
Wednesday, October 04, 2023 - 18:00
Location: Barcelona, Spain
Booth Number: 20

Visit Hovione at OPRD (Table #20), the Leading Process Chemistry Conference from 2-4 October in Barcelona. 

The chemical and pharma industries are fast moving and ever changing and the efficient conversion of a chemical process into a process for manufacture on tonnage scale has always been of importance. However, in the current economic and regulatory climate, it has become increasingly vital and challenging to do so efficiently and sustainably. 



The conference is the place to be to learn about the latest scientific updates in the industry and to network with chemical experts from around the globe.



Schedule a meeting with our experts (Table #20) to learn more about our focus on the development and manufacture of challenging products that demand the highest standards of process chemistry and manufacturing expertise coupled with rigorous regulatory compliance.

 

schedule a meeting

 

Schedule your meeting today 

 

More about Hovione Drug Substance

 



Find more about OPRD Barcelona

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026